17 results about "Low-substituted hydroxypropylcellulose" patented technology

A sublingual tablet and application thereof in desensitization therapy drug are provided. The sublingual tablet is a low-dose allergen sublingual tablet. The sublingual tablet includes freeze-dried powder of allergen protein, lactose, mannitol, low substituted hydroxypropyl cellulose, low moisture microcrystalline cellulose, and magnesium stearate. The freeze-drying process is adopted to obtain the freeze-dried powder of allergen protein, and the powder direct compression technology is adopted to obtain the sublingual tablet of allergen protein. The low-dose sublingual tablet has excellent properties, including appearance, hardness, tablet weight variation, disintegration time, taste, and uniformity of content, in particular has outstanding advantages in disintegration time, uniformity of content, stability, and preparation process, and has an industrial application prospect.

To provide a method for producing low-substituted hydroxypropyl cellulose having favorable disintegratability while maintaining sufficient compactibility.SOLUTION: A method for producing low-substituted hydroxypropyl cellulose having a hydroxypropoxy group content of 5 to 16 mass%, at least includes the steps of: bringing pulp into contact with and alkali metal hydroxide solution to obtain alkali cellulose; reacting the alkali cellulose with propylene oxide to obtain a reaction product; dispersing the reaction product into water containing at least acid to partially solubilize the reaction product, and then neutralizing the reaction product with an additional amount of acid to precipitate crude low-substituted hydroxypropyl cellulose; using a screw press to remove liquid from the crude low-substituted hydroxypropyl cellulose to obtain purified low-substituted hydroxypropyl cellulose having a water content of 50 to 60 mass%; and drying and pulverizing the purified low-substituted hydroxypropyl cellulose.SELECTED DRAWING: None

The present invention addresses the problem of providing a tablet which contains acotiamide or a salt thereof at a high concentration and which has not only a good elution property but also good storage stability.　The present invention relates to a tablet characterized by comprising granules that contain (A) acotiamide or a salt thereof, (B) pregelatinized starch, and (C) a disintegrant selected from low-substituted hydroxypropyl cellulose and sodium starch glycolate wherein the content of the component (A) in an uncoated tablet is 65-91 mass%.

The present invention relates to a novel formulation comprising a benzimidazole derivative. The formulation for oral administration comprising a compound of Formula 1 according to the present invention or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose, exhibits an excellent storage stability and has an effect on preventing a phenomenon of decline in dissolution rate, thus being usefully used as a formulation for oral administration.

The invention belongs to the technical field of veterinary oxytetracycline hydrochloride preparations, and provides a veterinary oxytetracycline hydrochloride orally disintegrating tablet and a preparation method thereof, the veterinary oxytetracycline hydrochloride orally disintegrating tablet comprises the following components by weight: 20-30% of oxytetracycline hydrochloride, 18-21% of a disintegrating agent, 48-52% of a filler, 2-4% of a lubricant, and 2-4% of a flavoring agent; wherein the disintegrating agent is composed of polyvinylpolypyrrolidone and low-substituted hydroxy propyl cellulose in a mass ratio of (1.5-3): 1, the filling agent is composed of a mixed auxiliary material and mannitol in a mass ratio of (2-4): 1, and the mixed auxiliary material is composed of microcrystalline cellulose and low-substituted hydroxy propyl cellulose in a mass ratio of (7-8): (2-3); the lubricant is prepared from superfine silica powder and magnesium stearate in a mass ratio of (1-5): 1, and the flavoring agent is prepared from stevioside and edible essence in a mass ratio of (4-6): 1. According to the technical scheme, the problems that in the prior art, a common tablet needs to be swallowed, the bitter taste is obvious, consequently, animals refer to eat, young livestock / poultry are difficult to take, gastrointestinal dissolution is slow, and the bioavailability is low are solved.

Provided is a method for producing low-substituted hydroxypropyl cellulose having high flowability and favorable compactibility. The method includes essentially the steps of: bringing a solution of alkali metal hydroxide into contact with a powder pulp to prepare alkali cellulose; allowing the alkali cellulose and propylene oxide to react with each other to obtain a reaction product; mixing the reaction product with water, as a solubilization step, without adding any acid; neutralizing the alkali metal hydroxide contained in the reaction product; washing, dewatering and drying the neutralized reaction product after being subjected to the neutralizing step to produce dried low-substituted hydroxypropyl cellulose; and pulverizing the dried low-substituted hydroxypropyl cellulose.

The invention discloses peimisine for inhibiting gastric cancer as well as application and a composition thereof, and relates to the technical field of application of peimisine compositions. The peimisine has the effect of inhibiting gastric cancer by inhibiting a PI3K / Akt signal channel. The preparation method comprises the following steps: mixing pregelatinized starch, a composite auxiliary material, lactose and a peimisine microcapsule, adding polyethylene glycol, sodium carboxymethyl starch and low-substituted hydroxy propyl cellulose, mixing, and tabletting to obtain the peimisine microcapsule tablet. The application proves that peimisine can be used for inhibiting gastric cancer, and peimisine micro-capsule tablets prepared from the composition of peimisine can form pH responsive release, reduce gastric mucosa stimulation, improve bioavailability and facilitate absorption of peimisine.

To provide a method for producing highly stable tablets containing Selexipag.SOLUTION: According to one embodiment of the present invention, there is provided a method for producing tablets containing Selexipag, comprising granulating additives to produce a granulated product, mixing the granulated product with Selexipag to obtain a mixture, and tableting the mixture, wherein the granulated product does not substantially contain Selexipag in the method for producing tablets containing Selexipag. The additive in the granulated product may include at least one selected from the group consisting of D-mannitol, hydroxypropyl cellulose, and low-substituted hydroxypropyl cellulose.SELECTED DRAWING: None

In the preparation process, mannitol and microcrystalline cellulose are used as filling agents, polyvinylpolypyrrolidone and low-substituted hydroxy propyl cellulose are used as disintegrating agents, and aspartame and menthol are used as taste masking agents, so that the problems of poor material fluidity, sticking, easiness in cracking during tabletting and the like are solved; by adopting a direct tabletting method, the adverse effect of high temperature and high humidity on the selexipag is reduced, and the selexipag tablet has the advantages of rapid disintegration within 30 seconds, rapid dissolution, better compressibility, better stability, good taste, simple preparation method and the like, is more suitable for patients with dysphagia, especially the old and children, has great clinical significance and is worthy of popularization and application. The method is suitable for large-scale industrial production.

The invention discloses a blonanserin orally disintegrating tablet composition and a preparation method thereof, and relates to the technical field of preparations. The blonanserin orally disintegrating tablet composition is prepared from the following components in parts by weight: 4 parts of blonanserin micro powder, 60 to 100 parts of a diluent, 10 to 30 parts of a disintegrating agent, 0.5 to 2 parts of an adhesive, 1 to 3 parts of a flow aid, 1 to 5 parts of a sweetening agent, 0.5 to 5 parts of a lubricating agent and 0.5 to 1.5 parts of a solubilizer, the disintegrating agent is a composition of low-substituted hydroxypropyl cellulose and polyvinylpolypyrrolidone, and the mass ratio of the addition amount of the low-substituted hydroxypropyl cellulose to the addition amount of the polyvinylpolypyrrolidone is (20-1): (10-5) in parts by weight of the disintegrating agent. The blonanserin and the solubilizer are matched for use, so that the dissolution rate of the blonanserin is greatly improved, and the disintegration time limit is further prolonged by matching with other components, namely the low-substituted hydroxy propyl cellulose and the cross-linked povidone, in the material.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cilostazol controlled-release preparation and a preparation method thereof. The preparation is based on a composite carrier composed of mesoporous silica and low-substituted hydroxy propyl cellulose, the cilostazol is highly dispersed in the composite carrier in an amorphous state through combination of ball milling pretreatment and a high-temperature fluidized bed melt dispersion process, and a final tablet is obtained through tabletting by adopting a step-by-step design of internally and externally adding a disintegrating agent. The dissolution rate of the cilostazol preparation prepared by the invention is greater than or equal to 80% within 15 minutes and greater than or equal to 95% within 30 minutes, so that rapid and stable drug release is realized, and the risk of burst release of the drug and adverse reaction caused by fluctuation of blood concentration are effectively reduced; and the preparation shows excellent stability, and an acceleration test (6 months) result shows that the increase of related substances of the preparation is less than or equal to 0.5%, the change rate of the dissolution rate is less than or equal to 3%, and the consistency and reliability of the curative effect in the clinical medication process can be effectively guaranteed.

To provide an apremilast solid preparation suppressed in increase of related substances with time and excellent in stability.SOLUTION: The apremilast solid preparation contains apremilast and an additive, wherein the additive contains at least one selected from the group consisting of low-substituted hydroxypropyl cellulose, crospovidone, glycerin fatty acid ester, hydrous silicon dioxide, and light anhydrous silicic acid. It is preferable that the additive does not contain at least one selected from the group consisting of a sodium salt, a calcium salt, and a magnesium salt.SELECTED DRAWING: None

An orodispersible tablet of pregabalin for oral administration comprising 15-60%w / w pregabalin or a pharmaceutically acceptable salt thereof; at least one diluent; a least one disintegrant comprising 0.1-10 %w / w; at least one lubricant comprising 0.1-5 %w / w; at least one binder comprising 0.1-10 %w / w; at least one glidant comprising 0.1-10 %w / w; and at least one or more pharmaceutically acceptable excipients; wherein the orodispersible table is disintegrated upon contact with saliva in less than 3 minutes. The diluent is preferably a combination of microcrystalline cellulose and mannitol; the disintegrant is preferably croscarmellose sodium; the binder is preferably low substituted hydroxypropyl cellulose; the glidant is preferably a combination of talc and colloidal anhydrous silica; and the lubricant is preferably magnesium stearate. The ratio of the lubricant to the diluent may be in the range of 1:70 to 1:90, preferably 1:75 to 1:85. The tablet may further comprise a sweetener, flavouring agent and / or sucralose. Methods of manufacturing the tablet via wet granulation are also provided. The tablet may release 85% of the pregabalin within 80 minutes, preferably within 60 minutes.

The application discloses a kind of micro-pellet type omeprazole enteric-coated capsules and preparation method thereof, including drug-containing pills, isolation layer and enteric layer, wherein the drug-containing pills comprise omeprazole, carboxymethyl chitosan, low-substituted hydroxypropyl cellulose, binder, filler and stabilizer;The mass ratio of omeprazole, carboxymethyl chitosan and low-substituted hydroxypropyl cellulose is 1:0.2-0.4:0.05-0.25;The micro-pellet type omeprazole enteric-coated capsule of the application does not contain organic solvent and surfactant, and the auxiliary material is simple, the micro-pellet particle size is uniform, the roundness is good, the surface finish is good, not easy to break, and the drug release effect is stable.

To provide a method for producing L-HPC having high flowability and favorable compactibility.SOLUTION: A method for producing low-substituted hydroxypropyl cellulose at least includes the steps of: bringing a powder pulp into contact with alkali metal hydroxide solution to obtain alkali cellulose; allowing the alkali cellulose to react with propylene oxide to obtain a reaction product; mixing the reaction product with water, as a solubilization step, without adding any acid; neutralizing the alkali metal hydroxide contained in the reaction product; washing, dewatering and drying the reaction product of after the neutralization step to obtain dried low-substituted hydroxypropyl cellulose; and pulverizing the dried low-substituted hydroxypropyl cellulose.SELECTED DRAWING: None

Provided is a method for producing low-substituted hydroxypropyl cellulose having favorable disintegratability while maintaining sufficient compactibility. The method essentially includes the steps of: bringing an alkali metal hydroxide solution into contact with a pulp to prepare alkali cellulose; reacting the alkali cellulose with propylene oxide to obtain a reaction product; dispersing the reaction product into a solution containing at least an acid to partially solubilize the reaction product, and then neutralizing the reaction product with an additional amount of acid to precipitate crude low-substituted hydroxypropyl cellulose; using a screw press to remove liquid from the crude low-substituted hydroxypropyl cellulose to obtain purified low-substituted hydroxypropyl cellulose having a water content of 50 to 60% by mass; and drying and pulverizing the purified low-substituted hydroxypropyl cellulose, wherein the method produces low-substituted hydroxypropyl cellulose having a hydroxypropoxy group content of 5.0 to 16.0% by mass.